BrazilCertara acquires German life sciences visualisation specialist BaseCase
US life sciences firm Certara has acquired BaseCase, a German data visualisation software as a service company.
Headquartered in Berlin, Germany, with offices in New York and Poland, BaseCase is a Software as a Service (SaaS) solution specialising in building interactive spreadsheet-driven web-apps for the pharmaceutical, medical device, and diagnostic industries. Since founding in 2007 by the Dutchman Gijs Hubben and Diarmuid Glynn, BaseCase’s software is today used by 70% of the top 10 pharma and MedTech companies and in over 60 countries worldwide.
The company’s visualisation software has gained popularity against a backdrop of increasing pressure for healthcare players to demonstrate the value delivered by new medications and devices. BaseCase’s interactive platform improves how life science companies communicate and present that value, whether to C-suite executives, physicians and healthcare providers, or to payers and health industry authorities.
Commenting on the acquisition of BaseCase, Thomas Kerbusch, President of Certara Strategic Consulting Services, said, “We are delighted with the deal and are looking forward to expanding the applications for its user-friendly, mobile communications technology. BaseCase’s interactive platform will enable pharmaceutical and medical technology companies to visualize model results and large, real-world datasets to make sound decisions quickly, within controlled communication cascades.”
Certara was formed in 2008 by the merger of Tripos International, a provider of drug discovery informatics products and services, with the Pharsight Corporation, a software and regulatory services provider focused on optimising clinical drug development. The Germany-headquartered company and its roughly 45 employees will be integrated into Certara’s Strategic Consulting Services division and serve as a key offering within Certara’s broader data science portfolio. Previously, Certara acquired Quantitative Solutions, an international pharmacometrics consulting company, as well as ClinGenuity (a solutions provider for clinical trial reporting) and Synchrogenix (a specialist in regulatory writing and submission services).
BaseCase CEO Gijs Hubben stated; “We are confident that we are a great match. Both companies have comparable cultures – entrepreneurial, dynamic, diverse, and quality driven – and possess a similar mix of scientific and software engineering staff. With the growing acceptance of modelling and simulation in life sciences, comes the need to simplify complex data science concepts and results. Certara is the perfect home for BaseCase.”
C-founder Glynn highlighted that Certara’s footprint, expertise in model-informed drug development, and financial muscle will enable BaseCase to not only grow its customer base (“we have already identified several joint expansion projects”), but also enable the team to accelerate the development of the software solution.
The deal was advised on by among others Hampleton Partners, a M&A consultancy specialised in technology sectors, which provided sell-side advisory to BaseCase. The project was managed by consultants Jonathan Simnett and Anton Røthe. “Hampleton’s team was very experienced and strategic in its approach, constantly hands-on and delivered exactly what it promised from the outset,” commented Hubben.
